ReviewInternational journal of molecular sciences2022
Current Knowledge on the Pathophysiology of Lean/Normal-Weight Type 2 Diabetes.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6.Diabetes, obesity & metabolism · 2025Trial
- Precision medicine in low-income settings and small island developing states.Nature reviews. Endocrinology · 2026Review
- Improving Precision Diagnosis and Treatment of Diabetes in Low-Resource Settings in Africa Through Structured Clinical Phenotyping: A Narrative Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
- Protective effects of buloxibutid and empagliflozin on hypertension-induced cardiac and vascular injury in rats.Journal of molecular histology · 2026Article
- Clinical characteristics and outcomes of lean diabetes mellitus in patients with moderate and severe aortic stenosis.Frontiers in cardiovascular medicine · 2026Article
- Lean type 2 diabetes: the overlooked epidemic reshaping global health.Diabetology & metabolic syndrome · 2025Review
- Ethnic diversity in precision medicine: a reality or an aspiration?Diabetologia · 2025Review
- Incident type 2 diabetes and its risk factors in men and women aged 40-60 years from four sub-Saharan African countries: results from the AWI-Gen study.The Lancet. Global health · 2025Article
- A sex-disaggregated analysis of the prognostic value of lean type 2 diabetes mellitus in the adult population with acute myocardial infarction.Cardiovascular diabetology · 2025Article
- Identification of genetic loci enriched in obese or lean T2D cases in the Korean population.Genes & genomics · 2025Article
- Oxidative Stress and Cardiovascular Complications in Type 2 Diabetes: From Pathophysiology to Lifestyle Modifications.Antioxidants (Basel, Switzerland) · 2025Review
- BMI and Mortality: The Diabetes-Obesity Paradox Examined in a Large US Cohort.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Review
- Lean diabetes: 20-year trends in its prevalence and clinical features among Korean adults.BMC public health · 2024Article
- Higher neighborhood disadvantage is associated with weaker interactions among cardiometabolic drivers.International journal of cardiology. Cardiovascular risk and prevention · 2024Article
- Reverse epidemiology of obesity paradox: Fact or fiction?Physiological reports · 2024Review
- Investigation of the risk factors associated with prediabetes in normal-weight Qatari adults: a cross-sectional study.Scientific reports · 2024Article
- Advances in the Insulin-Heart Axis: Current Therapies and Future Directions.International journal of molecular sciences · 2024Review
- Article
- Adipocytokines and Inflammation in Patients and a Gerbil Model: Implications for Obesity-Related and Nonobese Diabetes.Journal of diabetes research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since early times, being overweight and obesity have been associated with impaired glucose metabolism and type 2 diabetes (T2D). Similarly, a less frequent adult-onset diabetes in low body mass index (BMI) people has been known for many decades. This form is mainly found in developing countries, whereby the largest increase in diabetes incidence is expected in coming years. The number of non-obese patients with T2D is also on the rise among non-white ethnic minorities living in high-income Western countries due to growing migratory flows. A great deal of energy has been spent on understanding the mechanisms that bind obesity to T2D. Conversely, the pathophysiologic features and factors driving the risk of T2D development in non-obese people are still much debated. To reduce the global burden of diabetes, we need to understand why not all obese people develop T2D and not all those with T2D are obese. Moreover, through both an effective prevention and the implementation of an individualized clinical management in all people with diabetes, it is hoped that this will help to reduce this global burden. The purpose of this review is to take stock of current knowledge about the pathophysiology of diabetes not associated to obesity and to highlight which aspects are worthy of future studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.